A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)

Name: A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
Published: 2021
License: Public Domain

Merck Sharp & Dohme LLC · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

pembrolizumab pt renalcellcarcinoma

renal cell carcinoma, belzutifan, pembrolizumab, programmed cell death-1 (pd1), hypoxia inducible factor 2 alpha (hif-2 alpha), hypoxia inducible factor 2α (hif-2α), renal cell carcinoma (rcc), kidney cancer, mk-6482, mk6482, pt-2977, pt2977

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 993264
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.